Infobox company company name Genentech, Inc. company logo Image Genentech.svg 210px company type Wholly ... America br Rick Kentz, Legal br Marc Tessier Lavigne , Research br Denise Smith Hams, HR, Genentech ... employees c. 11,000 December 31, 2008 homepage http www.gene.com www.gene.com Genentech Inc. , or Genetic ... of Biotechnology author Eugene Russo work Nature date 2003 01 23 ref ref name Genentech CorporateOverview Genentech was founded by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer. After a meeting in 1976, the two decided to start the first biotechnology company, Genentech. cite web url http www.gene.com gene about corporate index.jsp?hl en&q genentech title Corporate Overview author Genentech ref It is considered to have founded the biotechnology industry. ref name Nature2003 01 23 ref name Genentech CorporateOverview One of its founders, Boyer, is considered to be a pioneer ... a new business, Genentech, to seek practical uses for Boyer and Cohen s engineered proteins ... insulin in 1978. As of March 2008, Genentech employed more than 11,000 people and Arthur D. Levinson ... title Genentech Inc. Google Finance accessdate 2008 05 05 ref The Swiss pharmaceutical conglomerate Hoffmann La Roche now completely owns Genentech after completing its purchase on March 26, 2009 for approximately ... 2008 09 26 title Roche Makes 43.7B Bid for Genentech work Genetic Engineering & Biotechnology News url http www.genengnews.com news bnitem.aspx?name 39080941 ref Research Genentech markets itself ... biology to protein chemistry to bioinformatics and physiology. Genentech scientists in these various ..., Tissue Growth and Repair, Neuroscience and Infectious Disease. Genentech recent hiring and acquisitions .... But for a small development group at Oceanside, Genentech s research facilities are located only ... 32, one of the Genentech headquarters newer buildings Genentech s corporate headquarters is at South ..., California . On March 17, 2006, Genentech announced its decision to construct a new fill ... more details
Nofootnotes date February 2008 Infobox SCOTUS case Litigants MedImmune, Inc. v. Genentech, Inc. ArgueDate October 4 ArgueYear 2006 DecideDate January 9 DecideYear 2007 FullName MedImmune, Inc. v. Genentech, Inc. Docket 05 608 USVol 549 USPage 118 Citation Prior Subsequent Holding Contrary to respondents assertion that only a freestanding patent invalidity claim is at issue, the record establishes that petitioner has raised and preserved the contract claim that, because of patent invalidity, unenforceability, and noninfringement, no royalties are owing. 427 F. 3d 958, reversed and remanded. SCOTUS 2006 Majority Scalia JoinMajority Roberts, Stevens, Kennedy, Souter, Ginsburg, Breyer, Alito Dissent Thomas LawsApplied MedImmune, Inc. v. Genentech, Inc. , Case citation 549 U.S. 118 2007 was a decision by the Supreme Court of the United States involving United States patent law patent law . It arose from a lawsuit filed by MedImmune which challenged one of the Cabilly patents issued to Genentech . One of the central issues was whether a licensee retained the right to challenge a licensed patent , or whether this right was forfeited upon signing of the license agreement. The case related indirectly ... of the dispute was a lengthy interference proceeding between Genentech and Celltech which led ... Genentech a patent term of 29 years. MedImmune was a licensee of the later Cabilly patent, but argued ... Patent and Trademark Office USPTO declared the patent invalid. However, Genentech has appealed ... Using Stock and Stock Options to Minimize Patent Royalty Payment Risks After Medimmune v. Genentech ... archives biotech patents genentech claims rejected on patent which was subject of recent supreme court decision.html Genentech Claims Rejected on Patent Which Was Subject of Recent ... double patenting rejection on Genentech s 29 year old patent Patent Baristas Blog . February 22 ... genentech hit with adverse patent ruling.html Genentech Hit with Adverse Patent Ruling . California ... more details
Bob or Robert Swanson may refer to Robert A. Swanson , cofounder of Genentech, a biotech company Bob Swanson driver , Indianapolis 500 and midget car driver Robert Swanson inventor , whistle inventor hndis Swanson, Bob ... more details
Summary Building 32, one of the newest buildings on Genentech s sprawling headquarters campus in South San Francisco, California . Photographed on September 13, 2006 by user Coolcaesar. Licensing GFDL self with disclaimers migration relicense ... more details
Alteon may refer to Alteon Corporation , part of Genentech , producers of Alagebrium Alteon Training an aircraft training school owned by The Boeing Company Alteon WebSystems a network products manufacturer disambig ... more details
Unreferenced date September 2007 The Cabilly patents are two US patents issued to Genentech which relate to the fundamental technology required for the artificial synthesis of antibody molecules . Citation needed date September 2007 The name refers to the lead inventor Shmuel Cabilly. There has been ongoing legal controversy surrounding these patents since the original filing in 1983. An interference between US patent 4,816,567 the original Cabilly patent issued to Genentech and US patent 4,816,397 the Boss patent issued to Celltech resulted in the issuance of a second Cabilly patent to Genentech in 2001. This new patent would therefore extend into 2018, an effective term of 29 years. A lawsuit filed by MedImmune , a licensee of the Cabilly patent, resulted in the United States Supreme Court case MedImmune, Inc. v. Genentech, Inc. which was decided in favor of MedImmune. Following the supreme court decision, the United States Patent and Trademark Office USPTO declared Genentech s patent invalid, but Genentech has appealed, and the patent will remain valid and enforceable until the process is completed. An important implication of this case is the affirmation that a licensee retains the right to challenge a licensed patent. The controversy has also called attention to the amount of time the USPTO takes to resolve Interference proceeding s, and has been cited in arguments for changing to a First to file patent system. References http www.californiabiotechlaw.com archives biotech patents genentech claims rejected on patent which was subject of recent supreme court decision.html Genentech Claims Rejected on Patent Which Was Subject of Recent Supreme Court Decision . California ... double patenting rejection on genentechs 29 year patent USPTO issues double patenting rejection on Genentech ... 16, 2005. http www.californiabiotechlaw.com archives biotech patents genentech hit with adverse patent ruling.html Genentech Hit with Adverse Patent Ruling . California Biotech Law Blog . September 30 ... more details
Summary Genentech has sponsored these DNA themed gateway signs throughout South San Francisco, California , which declare the city to be the Birthplace of Biotechnology. Photographed by user Coolcaesar on October 14, 2006. Licensing GFDL self with disclaimers migration relicense ... more details
Licensing Non free product cover Fair use image data Non free image data Description Cover of Omalizumab. Source Genentech Novartis Portion Branded cover only. Low resolution Sufficient resolution for illustration, but considerably lower resolution than original. other information Intellectual property owned by if 3 Genentech Novartis . Fair use rationale Non free image rationale Article Omalizumab Purpose Used for purposes of illustration in an educational article about the entity represented by the image. br The image is used as the primary means of visual identification of this article topic. Replaceability Protected by copyright, therefore a free use alternative won t exist. ... more details
This is a list of famous genetic engineers. For more information, see genetic engineering . Paul Berg created the first recombinant DNA molecules Herbert Boyer created the first genetically modified organism and co founded the first biotechnical company specialising in genetic engineering Genentech Stanley Cohen biochemist Stanley Cohen created the first genetically modified organism Rudolf Jaenisch created the first transgenic mouse Robert A. Swanson co founded the first biotechnical company specialising in genetic engineering Genentech Craig Venter leader of the group that made the first synthetic life synthetic genome Mycoplasma laboratorium Category Genetic engineering genetics stub ... more details
s of 2008 date December 26, 2008 ref On April 14, 2009, following Genentech s 47 billion merger ... Francisco based biotech powerhouse. He will lead Genentech s new board of directors and steer the integration of Genentech into Roche. The board will include Roche executives as well as external members. Levinson also will be an advisor to Genentech s research and early development center and will join the Scientific Resource Board, Genentech s external advisory group. Levinson will be nominated ... 10 12 genentechs and apple board member arthur levinson leaves google board title Genentech s And Apple ... Executive Officer of Genentech July 1995 to April 30, 2009 . He was named chairman of the board ... more details
Primary Indication width 100 Company 2008 ref name Genentech 2008 10 K http www.sec.gov Archives edgar data 318771 000031877109000003 form10 k 2008.htm , Genentech 2008 10 K. ref ref name Pfizer 2008 ... d10k.htm , Ista Pharmaceuticals 2008 10 K. ref 2007 ref name Genentech 2007 10 K http www.sec.gov Archives edgar data 318771 000031877108000004 form10 k 2007.htm , Genentech 2007 10 K. ref ref name ... 930553 000119312508050141 d10k.htm , Ista Pharmaceuticals 2007 10 K. ref 2006 ref name Genentech 2006 10 K http www.sec.gov Archives edgar data 318771 000031877107000004 form10 k 2006.htm , Genentech ... 2005 ref name Genentech 2005 10 K http www.sec.gov Archives edgar data 318771 000031877106000005 form10 k.htm , Genentech 2005 10 K. ref ref name Pfizer 2005 10 K http www.sec.gov Archives edgar data ... data 64978 000095012306003031 y18212e10vk.htm , Merck 2005 10 K. ref 2004 ref name Genentech 2004 10 K http www.sec.gov Archives edgar data 318771 000031877105000003 dna 10k 2004.htm , Genentech 2004 ... 2004 10 K. ref 2003 ref name Genentech 2003 10 K http www.sec.gov Archives edgar data 318771 000031877104000002 dna 10k 2003.htm , Genentech 2003 10 K. ref ref name Pfizer 2003 10 K http www.sec.gov ... 000089256904000307 a96815e10vk.htm , Allergan 2003 10 K. ref 2002 ref name Genentech 2002 10 K http www.sec.gov Archives edgar data 318771 000031877103000002 dna 10k 2002.htm , Genentech 2002 10 ... y58494ex13.htm , Pfizer 2001 10 K. ref 2000 ref name Genentech 2000 10 K http www.sec.gov Archives edgar data 318771 000031877101500003 form10 k.txt , Genentech 2000 10 K. ref ref name Eli Lilly ... Pfizer 312 367 344 216 trastuzumab Herceptin HER2 positive metastatic breast cancer Genentech 1,382 ... small cell lung cancer NSCLC , renal cell carcinoma, HER2 negative breast cancer Genentech 2,686 2,296 1,746 1,132 554.6 erlotinib Tarceva Advanced metastatic non small cell lung cancer NSCLC Genentech ... 286.8 248.5 250.9 rituximab Rituxan Non Hodgkin s lymphoma and rheumatoid arthritis Genentech 2,587 ... more details
Tanox was a biopharmaceutical company based in Houston, Texas . The company was founded by two biomedical research scientists, Nancy T. Chang and Tse Wen Chang in March 1986. Nancy was the President and CEO of the company in its 21 year history, while Tse Wen was responsible for creating most of the company s proprietary technology and patent patents . Tanox s major technology was based on a series of inventions and a family of dominant patents pertaining to the use of humanized antibody humanized antibodies for targeting IgE and IgE expressing B lymphocyte B lymphocytes for the treatment of allergic diseases. Tanox started the anti IgE program and developed prototype antibody candidates in 1987. It formed a collaborative partnership with Ciba Geigy in 1990 to jointly develop the anti IgE program Ciba Geigy merged with Sandoz to form Novartis in 1996 . The Phase I clinical trial of CGP 51901, the chimeric antibody form of the humanized anti IgE antibody, TNX 901 , was carried out in Southampton, England in 1991. A successful Phase II trial in patients with severe allergic rhinitis toward mountain cedar pollens was performed in three medical centers in Texas in 1994 1995. In 1996, Tanox, Novartis, and Genentech formed a tripartite partnership to develop the anti IgE program. A humanized anti IgE antibody from Genentech, omalizumab , with identical binding characteristics as TNX 901, was chosen by a joint program steering committee for further development, because it had a better developed manufacturing process. Omalizumab, with the trade name Xolair , was approved by the U.S. Food and Drug Administration FDA in 2003 for use in patients 12 years and older with moderate to severe allergic asthma . It was subsequently approved in the European Union and many other countries for patients 12 years and older with severe allergic asthma. Tanox held an initial public offering and was listed in the NASDAQ in 2000. It was acquired by Genentech in August 2007 Genentech itself be ... more details
release regarding suspension format PDF work accessdate 2009 02 20 ref In April, 2009, Genentech Inc ... press release title Genentech Announces Voluntary Withdrawal of Raptiva from the U.S. Market publisher Genentech, Inc. date 2009 04 08 url http www.drugs.com news genentech announces voluntary raptiva ... more details
David Goeddel born 1951 in San Diego is a pioneer of the biotechnology industry who, employed at the time by Genentech , successfully used genetic engineering to coax bacteria into creating synthetic human insulin , human growth hormone , and human TPA for use in therapeutic medicine. By contrast, the pharmaceutical industries had been researching synthetically created versions of those proteins. Recruited by Robert A. Swanson Bob Swanson in 1978, he was the first non university scientist to be hired ref name Forbes1999 cite web url http members.forbes.com asap 1999 0531 090a 2.html title Biotechnology All Stars author Eric W. Pfeiffer publisher Forbes date 1999 05 31 ref at Genentech , and the company s third employee. ref name Forbes1999 Goeddel became legendary in the biotechnology and molecular biology fields by cloning virtually all of Genentech s early products and or processes, including synthetic insulin , growth hormone , and TPA , often beating out bigger and more established laboratories in the process. Besides being perhaps the single most important contributor to Genentech s rise to one of the nation s premier biotech companies, his extraordinary drive and competitive work ethic embodied Genentech s early Clone or Die culture ref name Invisible Frontiers Invisible Frontiers The Race to Synthesize a Human Gene by Stephen S. Hall 1987, Tempus Books of Microsoft Press ref Together with Steve McKnight and Robert Tjian , he founded Tularik in 1991, and was their president and CEO until Tularik was acquired by Amgen for 1.3 billion dollars in 2004 ref cite web url http www.amgen.com media media pr detail.jsp?year 2004&releaseID 509295 title Amgen to Acquire Tularik for 1.3 Billion date 2004 03 29 author Amgen publisher Amgen ref Goeddel earned his bachelor s degree in chemistry from the University of California, San Diego , and his PhD from the University of Colorado, Boulder . He is a member of the United States National Academy of Sciences National Academy ... more details
trials Genentech started clinical trial s on the drug in October 1996. ref cite web title Genentech Reports 1996 Third Quarter Results work Genentech date October 21, 1996 accessdate January 31, 2009 ... II clinical trial results showed that erlizumab did not meet Genentech s goals. ref name genentech announces Genentech s primary goal was for the drug to increase blood flow to the heart within 90 minutes ... more details
name NYT ref name Genentech http www.gene.com gene research sci profiles neurosci t lavigne profile.html Marc Tessier Lavigne Executive Vice President Research and Chief Scientific Officer , Genentech ... 09 09 business 09gene.html Genentech Scientist to Lead Rockefeller University , The New York Times ... Genentech following its acquisition by Hoffmann La Roche Roche in March 2009. The departure of Tessier ... on the firm s scientific culture. Tessier Lavigne stated that his choice to leave Genentech was unrelated ... from Genentech. Russell L. Carson, chairman of the board of trustees at Rockefeller University said ..., called the move part of the tradition of exchange between academia and Genentech. ref name NYT ... more details
drugbox type mab image mab type mab source zu target IFN CAS number 948570 30 7 ATC prefix none ATC suffix PubChem DrugBank chemical formula C 6486 H 9990 N 1722 O 2026 S 44 molecular weight 145.9 kDa bioavailability protein bound metabolism elimination half life excretion pregnancy AU pregnancy US pregnancy category legal AU legal CA legal UK legal US legal status routes of administration Rontalizumab is a humanized monoclonal antibody ref http www.who.int medicines publications druginformation innlists PLFinal101.pdf WHO Drug Information ref being developed by Genentech ref http www.gene.com gene pipeline status immunology rhumab ifnalpha Genentech Rontalizumab rhuMAb IFN alpha ref . as of 2009 11 , it is being investigated in a clinical trial or the treatment of systemic lupus erythematosus . ref ClinicalTrialsGov NCT00962832 A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus ROSE ref References reflist Monoclonals for immune system monoclonal antibody stub ... more details
refimprove date January 2009 Napoleone Ferrara , M.D. , Ph.D. is an Italian American molecular biologist and is currently a Genentech Fellow in tumor biology and angiogenesis. He is credited with identifying the human Vascular endothelial growth factor VEGF gene and describing its angiogenesis proangiogenic properties, which formed the basis for the development of Genentech s bevacizumab and Lucentis monoclonal antibody treatments. For his VEGF discovery, he won a Lasker Award in 2010. ref cite web url http www.laskerfoundation.org awards 2010 c description.htm title 2010 Winners Lasker DeBakey Clinical Medical Research Award author Strauss, Evelyn publisher The Lasker Foundation accessdate 2010 11 11 ref Education Dr. Ferrara received his medical degree from the Facolt di Medicina e Chirurgia dell Universit di Catania University of Catania Medical School in Italy in 1981, and joined Genentech in 1988. ref http www.sciencedirect.com science? ob ArticleURL& udi B6T64 4FYG6N7 5& user 4429& rdoc 1& fmt & orig search& sort d&view c& acct C000059602& version 1& urlVersion 0& userid 4429&md5 0c53e7083cf75f478bba859312458ba4 Napoleone Ferrara discusses Avastin and the future of anti angiogenesis therapy , ScienceDirect. ref References reflist Persondata Metadata see Wikipedia Persondata . NAME Ferrara, Napoleone ALTERNATIVE NAMES SHORT DESCRIPTION DATE OF BIRTH PLACE OF BIRTH DATE OF DEATH PLACE OF DEATH DEFAULTSORT Ferrara, Napoleone Category Year of birth missing living people Category Living people Category Italian scientists Category Molecular biologists italy biologist stub ... more details
For other people named Robert Swanson Bob Swanson disambiguation Infobox Person name Robert A. Swanson image Replace this image male.svg image size 150px caption Robert A. Swanson birth name Robert birth date 1947 birth place U.S.A death date 1999 death place death cause brain cancer resting place resting place coordinates residence nationality United States other names known for Genentech biotechnology education MIT employer occupation biotechnologist home town title salary networth height weight term predecessor successor party boards religion spouse partner children parents relatives signature website footnotes Robert A. Swanson 1947 1999 was a venture capitalist who cofounded the biotechnology giant Genentech in 1976 with Herbert Boyer . Genentech is a pioneer in the field, and it remains one of the leading biotech companies in the world. He held an B.S. degree in Chemistry from MIT as well as a MIT Sloan School of Management Master s degree in Management M.B.A. from the MIT Sloan School of Management . Both degrees were conferred in 1970. He is regarded as an instrumental figure in launching the biotechnology revolution. The authors of the book, 1,000 Years, 1,000 People Ranking the Men and Women Who Shaped the Millennium ranked Mr. Swanson number 612. Mr. Swanson was inducted into the Junior Achievement U. S. Business Hall of Fame in 2006. ref http web.mit.edu newsoffice 1999 swanson 1208.html Robert Swanson, 52, alumnus who launched biotechnology industry, MIT News Office ref On 6 December , 1999, he succumbed to brain cancer , at the age of 52. ref http www.nature.com nature journal v403 n6767 full 403264a0.html Access Nature Bot generated title ref External links http www.accessexcellence.org RC AB BC Robert Swanson.html AccessExcellence.org References Reflist Persondata Metadata see Wikipedia Persondata . NAME Swanson, Robert A. ALTERNATIVE NAMES SHORT DESCRIPTION DATE OF BIRTH PLACE OF BIRTH U.S.A DATE OF DEATH PLACE OF DEATH DEFAULTSORT Swanson, Robert A ... more details
Dr. Arthur Riggs , Ph.D, is a geneticist who worked with Genentech to gene expression express the first artificial gene in bacteria . His work was critical to the modern biotechnology industry because it enabled the large scale manufacturing of protein drugs , including insulin . In 2006, Riggs was elected to the United States National Academy of Sciences National Academy of Sciences . He is the director emeritus of the Beckman Research Institute of City of Hope National Medical Center , where he was also the founding dean of City of Hope s graduate school. Riggs also serves on the board of trustees at the Keck Graduate Institute of Applied Life Sciences . Background Riggs earned his undergraduate degree in chemistry at University of California, Riverside in 1961, and was honored as a distinguished alumnus in 1988 http www.alumni.ucr.edu 50th 50 award recipients.html . He conducted his doctoral thesis work at the California Institute of Technology with Herschel K. Mitchell http www.pnas.org cgi reprint 55 3 599 . As graduate students at Caltech, he and Joel A. Huberman collaborated on work that later led to a classic paper on mammal ian DNA replication , which was published in 1966 http www.ncbi.nlm.nih.gov entrez query.fcgi?cmd Retrieve&db PubMed&list uids 5689363&dopt Citation . His postdoctoral work at the Salk Institute resulted in another well known series of papers on the lac repressor and bacteria l gene regulation . Genentech Along with fellow City of Hope researcher Keiichi Itakura , Riggs collaborated with Genentech scientist Herbert Boyer , and used recombinant DNA technology to become the first to produce a human protein in Escherichia coli E. coli . Following the advice of Riggs and Itakura, the group successfully produced the hormone Somatostatin in 1977 as a proof of concept before they attempted to work with the more complicated insulin molecule. http www.nap.edu books 0309051894 html 167.html The group succeeded in producing insulin in 1978, and in 1979 ... more details
refimprove date October 2009 Regis McKenna is best known for helping start several Silicon Valley firms during the 1970s and 1980s with his own marketing firm, Regis McKenna, Inc. , founded in 1970. ref http www.regis.com Regis McKenna official website . ref McKenna retired from consulting in 2000 and is concentrating his efforts on high tech entrepreneurial seed ventures. McKenna and his firm worked with a number of Start up company start up companies during their formation years including America Online , Apple Inc. Apple , Compaq , Electronic Arts , Genentech , Intel , Lotus Software , Microsoft , National Semiconductor , Silicon Graphics , 3COM , and others. References reflist DEFAULTSORT Mackenna, Regis Category Year of birth missing living people Category Living people Category American computer businesspeople Category Silicon Valley people US business bio stub bg fi Regis McKenna ... more details
drugbox verifiedrevid 403144242 type mab image mab type mab source zu target Interleukin 13 IL 13 CAS number 953400 68 5 ATC prefix none ATC suffix PubChem DrugBank KEGG D09633 chemical formula molecular weight bioavailability protein bound metabolism elimination half life excretion pregnancy AU pregnancy US pregnancy category legal AU legal CA legal UK legal US legal status routes of administration Lebrikizumab is a humanize d monoclonal antibody and an immunosuppresive drug for the treatment of asthma . as of September 2009 , it is undergoing Phase II clinical trials . ref http www.clinicaltrials.gov ct2 results?term lebrikizumab ClinicalTrials.gov ref ref http www.gene.com gene pipeline status immunology anti il13 Genentech Lebrikizumab anti IL13 ref References reflist Monoclonals for immune system immunosuppressants monoclonal antibody stub antineoplastic drug stub ... more details
unreferenced date May 2010 The Advanced Computation Group ACG is a group within Apple Inc . The ACG researches algorithms and high performance issues relevant to Apple technology. ACG concentrates on Mac OS X for computer science Relationship with other fields scientific applications , Vectorization computer science vectorization , tutorials, algorithm implementations for specific Apple products and joint research and development with outside partners. One particularly high profile project of the ACG is Apple Genentech BLAST an algorithm for comparing biological sequences, such as the amino acid sequences of different proteins which runs several times faster on Power Mac and Xserve than generic BLAST runs on other platforms. This implementation is open source software developed in cooperation with Genentech . The ACG also developed Apple s Xgrid , which is clustering and distributed computing software for Macintosh computers, allowing central processing unit processor intensive applications to borrow processing power from other computers on their network. Much of the work of the ACG has been directed toward advanced uses of PowerPC processors which have run Macintosh computers since the 1990s. Now that Apple has completed their Apple Intel transition transition to Intel processors , the ACG s work is increasingly focused on that new platform. External links http www.apple.com acg ACG web site http www.apple.com acg archive.html ACG archive primarily concerned with PPC architecture, but much is also applicable to Intel architecture http developer.apple.com opensource tools blast.html A G BLAST Apple Category Apple Inc. Category Cluster computing ... more details
drugbox verifiedrevid 408539538 type mab image mab type mab source zu o target HER2 CAS number 380610 27 5 ATC prefix none ATC suffix PubChem DrugBank KEGG Ref keggcite correct kegg KEGG D05446 chemical formula molecular weight bioavailability protein bound metabolism elimination half life excretion pregnancy AU pregnancy US pregnancy category legal AU legal CA legal UK legal US legal status routes of administration Pertuzumab also called 2C4 , trade name Omnitarg is a monoclonal antibody . The first of its class in a line of agents called HER dimerization inhibitors . By binding to HER2 , it inhibits the protein dimer dimer ization of HER2 with other HER receptors, which is hypothesized to result in slowed cancer tumor growth. ref name JCO deBono cite journal last de Bono first Johann S. title Open Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy Naive Patients With Hormone Refractory Prostate Cancer journal Journal of Clinical Oncology volume 25 issue 3 pages 257 262 date 20 January 2007 id doi 10.1200 JCO.2006.07.0888 pmid 17235043 last2 Bellmunt first2 J last3 Attard first3 G last4 Droz first4 JP last5 Miller first5 K last6 Flechon first6 A last7 Sternberg first7 C last8 Parker first8 C last9 Zugmaier first9 G ref Pertuzumab is currently being developed by Genentech . Early clinical trials of pertuzumab in prostate, breast, and ovarian cancers have been met with limited success. ref http www.gene.com gene news press releases display.do?method detail&id 8431 Genentech press release May 15, 2005 ref References references Monoclonals for tumors Category Monoclonal antibodies monoclonal antibody stub it Pertuzumab ... more details
Infobox person name Susan Desmond Hellmann image Susan Desmond Hellmann.jpg alt in 2010 in Seattle caption birth date Birth date YYYY MM DD birth place death date Death date and age YYYY MM DD YYYY MM DD death date then birth date death place nationality other names known for public health occupation Chancellor education chancellor Susan Desmond Hellmann , MD, MPH, is currently the Chancellor of the University of California, San Francisco . She was appointed to the position by UC President Mark Yudof on May 7, 2009, and officially took over in the position on August 3, 2009. ref name UCSFPub 1 cite web url http www.ucsfhealth.org adult health library news 2009 05 121510.html accessdate 2009 08 03 title UCSF press release ref She served as president of New product development product development at Genentech from March 2004 through April 30, 2009. In this role, Desmond Hellmann was responsible for Genentech s development, process research and development , business development , Product management product portfolio management , alliance management, and pipeline planning support functions. Desmond Hellmann also served as a member of Genentech s executive committee, beginning in 1996. Desmond Hellmann joined Genentech in 1995 as a clinical scientist, and she was named Chief Medical Officer chief medical officer in 1996. In 1999, Desmond Hellmann was named executive vice president of development and product operations. Desmond Hellmann is board certified in internal medicine and Oncology medical oncology , and completed her clinical training at UCSF following completion of a Bachelor of Science bachelor of science degree in premedicine and a Doctor of Medicine medical degree at University of Nevada, Reno . She also holds a master s degree in public health from University of California, Berkeley . Prior to joining Genentech, Desmond Hellmann was associate director of clinical cancer research at Bristol Myers Squibb Pharmaceutical Research Institute. While at Bristol Myer ... more details
Encyclopedia
top
